Novocure (NASDAQ:NVCR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Sunday, Market Beat reports. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates […]
